Home > News > BioSante Pharmaceuticals Announces Positive Results
April 29th, 2004
BioSante Pharmaceuticals Announces Positive Results
BioSante Pharmaceuticals, Inc. today announced that a comparative preclinical study demonstrated its calcium phosphate nanotechnology-based vaccine adjuvant, BioVant(TM), may be more effective than aluminum salt derivatives, the only adjuvant currently approved by the Food and Drug Administration. The study was conducted in collaboration with the U.S. Centers for Disease Control and Prevention in a previously unannounced BioSante collaboration.
Single-Cell Transfection Tool Enables Added Control for Biological Studies: McCormick researchers develop method of delivering molecules into targeted cells May 22nd, 2013
How Gold Nanoparticles Can Help Fight Ovarian Cancer May 21st, 2013
MU Researchers Develop Radioactive Nanoparticles that Target Cancer Cells: This is an early step toward developing therapies for metastasized cancers, MU scientist says May 21st, 2013
Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013